Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon


  1.  Refereed Papers Included in Science Citation Index:
  1. 2,5 Yen FS, Wei JC, Hung YT, Hsu CY, Hwu CM*, Hsu CC. Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes. Front Microbiol. 2023 Feb 17;14:1118000. doi: 10.3389/fmicb.2023.1118000. (IF: 5.2)
  2. 2,5 Yen FS, Hou MC, Liu JS, Hsu CC, Hwu CM*. Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes. Front Med (Lausanne). 2023 Jan 4;9:962337. (IF: 3.9)
  3. 2,5Yen FS, Wei JC, Shih YH, Hsu CC, Hwu CM*. Impact of individual microvascular disease on the risks of macrovascular complications in type 2 diabetes: a nationwide population-based cohort study. Cardiovascular Diabetology. 2023 May 9;22(1):109. (IF: 9.3)
  4. 2,5Yen FS, Lee PC, Hwu CM*. Is a low-carbohydrate, high-fat diet feasible for people with type 2 diabetes and nonalcoholic fatty liver disease? J Diabetes Investig. 2023 Aug;14(8):930-932. (IF: 3.2)
  5. 2,5Williamson A, Norris DM, Yin X, …, Hwu CM, et al. Genome-wide association study and functional characterization identifies candidate genes for insulin-stimulated glucose uptake. Nat Genet. 2023 Jun;55(6):973-983. (IF: 30.8)
  6. 2,5Yen FS, Chang SH, Wei JC, Shih YH, Hwu CM*. Respiratory Outcomes of Insulin Use in Patients with COPD: A Nationwide Population-Based Cohort Study. Pharmaceuticals (Basel). 2023 Apr 24;16(5):643. (IF: 4.6)
  7. 2,5Yen FS, Hou MC, Cheng-Chung Wei J, Shih YH, Hsu CY, Hsu CC, Hwu CM*. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes. Clin Gastroenterol Hepatol. 2023 Jun 16:S1542-3565(23)00482-2. (IF: 12.6)
  8. 2,4Yeh YK, Yen FS, Hwu CM*. Diet and exercise are a fundamental part of comprehensive care for type 2 diabetes. J Diabetes Investig. 2023 Aug;14(8):936-939. (IF: 3.2)
  9. 2,4Huang WC, Chen YY, Yang SY, Lai CF, Lai TS, Chen HY, Chen L, Wang YJ, Cheng YL, Lang CL, Chen CF, Chang HF, Peng JK, Lin LY, Cheng HM, Hwu CM, Lu TM, Chueh JS, Lin YH, Wu VC. Fat mass as an important predictor of persistent hypertension in patients with primary aldosteronism after adrenalectomy. Hypertens Res. 2023 Jun;46(6):1375-1384 (IF: 5.4)
  10. 2,5Chiu CH, Hsuan CF, Lin SH, Hung YJ, Hwu CM, Hee SW, Lin SW, Fong SW, Hsieh PC, Yang WS, Lin WC, Lee HL, Hsieh ML, Li WY, Lin JW, Hsu CN, Wu VC, Chuang GT, Chang YC, Chuang LM. ER ribosomal-binding protein 1 regulates blood pressure and potassium homeostasis by modulating intracellular renin trafficking. J Biomed Sci. 2023 Feb 19;30(1):13. (IF: 11.0)
  11. 2,5Yang YH, Chang YL, Lee BC, Lu CC, Wang WT, Hu YH, Liu HW, Lin YH, Chang CC, Wu WC, Tseng FY, Lin YH, Wu VC, Hwu CM. Strategies for subtyping primary aldosteronism.

Source: Journal of the Formosan Medical Association. 2023 May 16:S0929-6646(23)00155-9. (IF: 3.2)

  1. 2,5Huang CW, Tu KH, Fan KC, Tsai CH, Wang WT, Wang SY, Wu CY, Hu YH, Huang SH, Liu HW, Tseng FY, Wu WC, Chang CC, Lin YH, Wu VC, Hwu CM. The role of confirmatory tests in the diagnosis of primary aldosteronism. J Formos Med Assoc. 2023 May 10:S0929-6646(23)00148-1. (IF: 3.2)
  2. 2,5Ho LJ, Sheu WH, Lo SH, Yeh YP, Hwu CM, Huang CN, Hsieh CH, Kuo FC. Unhealthy lifestyle associated with increased risk of macro- and micro-vascular comorbidities in patients with long-duration type 2 diabetes: results from the Taiwan Diabetes Registry. Diabetol Metab Syndr. 2023 Mar 8;15(1):38. (IF: 4.8)
  3. 2,4Tseng CH, Tseng CL, Chen HS, Chen PL, Huang CJ*. Clinical characteristics of neutropenic patients under antithyroid drug: Twelve-year experience in a medical center. J Chin Med Assoc. 2023 Sep 1;86(9):826-834. (IF: 3.0)
  4. 2,4Hang JF, Chen JY, Kuo PC, Lai HF, Lee TL, Tai SK, Kuo CS, Chen HS, Li WS, Li CF. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases. Mod Pathol. 2023 Sep;36(9):100242. (IF: 7.5)
  5. 2,5Lin WC, Chen WC, Wang PW, Chan YC, Chang YH, Chen HS, Chen ST, Chen WC, Cheng KL, Chi SY, Chiang PL, Chou CK, Chou FF, Huang SC, Liu FH, Luo SD, Tseng FY, Wang CY, Wang WH, Wu MH. 2022 Taiwan clinical multicenter expert consensus and recommendations for thyroid radiofrequency ablation. Ultrasonography. 2023 Jul;42(3):357-375. (IF: 3.1)
  6. 2,5Lu YW, Tsai CT, Chou RH, Tsai YL, Kuo CS, Huang PH, Lin SJ. Sex difference in the association of the triglyceride glucose index with obstructive coronary artery disease. Scientific Reports. 2023 Jun 14;13(1):9652. (IF: 4.6)
  7. 2,4Chen CY, Leu HB, Wang SC, Tsai SH, Chou RH, Lu YW, Tsai YL, Kuo CS, Huang PH, Chen JW, Lin SJ. Inhibition of Trimethylamine N-Oxide Attenuates Neointimal Formation Through Reduction of Inflammasome and Oxidative Stress in a Mouse Model of Carotid Artery Ligation. Antioxidants & Redox Signaling. 2023 Jan;38(1-3):215-233. (IF: 6.6)
  8. 2,4 Pan LH, Yen CC, Huang CJ, Ng XN, Lin LY. Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience. Front Endocrinol (Lausanne). 2023 Mar 10;14:1134643. (IF: 5.2)
  9. 2Chang TT, Li SY, Lin LY, Chen C, Chen JW. Macrophage inflammatory protein-1β as a novel therapeutic target for renal protection in diabetic kidney disease. Biomed Pharmacother. 2023 May;161:114450. (IF: 7.5)
  10. 2 Chen C, Lin LY, Chen JW, Chang TT. CXCL5 suppression recovers neovascularization and accelerates wound healing in diabetes mellitus. Cardiovasc Diabetol. 2023 Jul 7;22(1):172. (IF: 9.3)
  11. 2 Wu SY, Wu CY, Lin LY, Chen YH, Huang HY, Lai YL, Lee SY. Systemic antibiotics adjuvants to scaling and root planing in type 2 diabetic and periodontitis individuals: Systematic review with network meta-analysis. Jpn Dent Sci Rev. 2023 Dec;59:167-178. (IF: 6.6)
  12. 2Huang CJ, Lee LH, Cheng CP, Chen HS, Hwu CM, Tang KT, Shih CW, Yeh CC, Wang FF, Yang CC. Analytical validation of an inductively coupled plasma mass spectrometry method for urinary iodine concentration measurements in Taiwan. J Formos Med Assoc. 2023 Aug;122(8):757-765. (IF: 3.2)
  13. 2 Huang CJ, Lee LH, Cheng CP, Yao SF, Chen HS, Hwu CM, Tang KT, Wang FF, Shih CW, Yang CC*, Huang WS*. Measurements of elemental iodine in soy sauces in Taiwan using a modified microplate method. Front Endocrinol (Lausanne). 2023 Mar 9;14:1058695. (IF: 5.2)
  14. 2 Ying TH, Huang CJ, Hsieh CJ, Wu PJ, Yeh CC, Hung PK, Chang WH, Wu MH, Hung H, Chang JW, Wang CT, Arcega RD, Mahmudiono T, Lee CC*, Chen HL*. Potential Factors Associated with the Blood Metal Concentrations in Reproductive Age Women in Taiwan. (Equal to first author.) Exposure and Health 2023 March 10 (IF: 6.7)
  15. 2 Huang CJ, Lu CH Lu; Shih KC. Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study. Eur J Drug Metab Pharmacokinet. 2023 Nov;48(6):665-674. (IF: 1.9)
  16. 2 Huang CJ, Li JZ, Hwu CM, Chen HS, Yeh CC, Wang FF, Yang CC. Determination of the Elemental Iodine in Human Breast Milk by Inductively Coupled Plasma mass Spectrometry. Biol Trace Elem Res. 2023 Jul 28 (IF: 3.9)
  17. 2 Huang CC, Shen HC, Lin R, Yang YY, Chang YC, Liao TL, Huang SF, Lin HC, Hou MC. Preservation of vascular endothelial glycocalyx and barrier by activation of adenosine A2A receptor (A2AR) improved renal dysfunction in cirrhotic rats. J Pharmacol Sci. 2023 May;152(1):50-60. (IF: 3.5)
  18. 2,5Hsu CY, Sheu WH, Lee IT. Brain-derived neurotrophic factor associated with kidney function. Diabetol Metab Syndr. 2023 Feb 13;15(1):16. (IF: 4.8)
  19. 2,4Ou SM, Tsai MT, Lee KH, Tseng WC, Yang CY, Chen TH, Bin PJ, Chen TJ, Lin YP, Sheu WH, Chu YC, Tarng DC. Prediction of the risk of developing end-stage renal diseases in newly diagnosed type 2 diabetes mellitus using artificial intelligence algorithms. BioData Min. 2023 Mar 10;16(1):8. (IF: 4.5)
  20. 2,5 Sheen YJ, Wang JM, Tsai PF, Lee WJ, Hsu YC, Wang CY, Sheu WH*. Accuracy of Point-of-Care Blood Glucometers in Neonates and Critically Ill Adults. Clin Ther. 2023 Jul;45(7):643-648. (IF: 3.2)
  21. 2,5 Luo Y, Chang Y, Zhao Z, Xia J, Xu C, Bee YM, Li X, Sheu WH, McGill M, Chan SP, Deodat M, Suastika K, Thy KN, Chen L, Shan Kong AP, Chen W, Deerochanawong C, Yabe D, Zhao W, Lim S, Yao X, Ji L. Device-supported automated basal insulin titration in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Lancet Reg Health West Pac. 2023 Mar 24;35:100746. (IF: 7.1)
  22. 2,4 Sheu WH*. Toward better diabetes care: Exploration and implementation. J Diabetes Investig. 2023 May;14(5):640-644. (IF: 3.2)
  23. 2,5Kim DJ, Sheu WH, Chung WJ, Yabe D, Ha KH, Nangaku M, Tan EC, Node K, Yasui A, Lei W, Lee S, Saarelainen L, Deruaz-Luyet A, Kyaw MH, Seino Y; EMPRISE East Asia Study Group. Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study. J Diabetes Investig. 2023 Mar;14(3):417-428. (IF: 3.2)
  24. 2,4 Jan YT, Tsai PS, Huang WH, Chou LY, Huang SC, Wang JZ, Lu PH, Lin DC, Yen CS, Teng JP, Mok GSP, Shih CT, Wu TH. Machine learning combined with radiomics and deep learning features extracted from CT images: a novel AI model to distinguish benign from malignant ovarian tumors. Insights into Imaging. 2023 Apr 24;14(1):68. (IF: 4.7)
  25. Pan LH, Chen YY, Pan CT, Hsu CY, Tseng CS, Yen IW, Chan CK, Lin LY. Follow-up care and assessment of comorbidities and complications in patients with primary aldosteronism: The Clinical Practice Guideline of the Taiwan Society of Aldosteronism. J Formos Med Assoc. 2023 Aug 22;S0929-6646(23)00324-8 (IF:3.9)
  26. Su GY, Ning NX, Lin KH, Hwu CM* Low-Density Lipoprotein Cholesterol is not a Major Determinant of High Sensitivity C-Reactive Protein Levels in People without Known Diabetes Mellitus Metab Syndr Relat Disord. 2023 Dec;21(10):567-572. (IF: 2.1)
  27. Chen LC, Huang WC, Peng KY, Chen YY, Li SC, Syed Mohammed Nazri SK, Lin YH, Lin LY, Lu TM, Kim JH, Azizan EA, Hu J, Li Q, Chueh JS, Wu VC; TAIPAI Study Groupi. Identifying KCNJ5 Mutation in Aldosterone-Producing Adenoma Patients With Baseline Characteristics Using Machine Learning Technology. JACC Asia. 2023 Jun 13;3(4):664-675. (IF:1.8)
  28. Wu TH, Su GY, Liu TY, Wang HT, Hwu CM*. Urinary acrolein protein conjugates-to-creatinine ratio is positively associated with diabetic peripheral neuropathy in patients with type 2 diabetes mellitus. Endocr Connect. 2023 Oct 5;12(11):e230253. (IF:2.9)
  29. Yen FS, Hou MC, Cheng-Chung Wei J, Shih YH, Hsu CY, Hsu CC, Hwu CM*. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.
    Source: Clin Gastroenterol Hepatol. 2023 Jun 16;S1542-3565(23)00482-2(IF:12.6)
  30. Huang CJ, Li JZ, Hwu CM, Chen HS, Wang FF, Yeh CC*, Yang CC*. Huang CJ, Li JZ, Hwu CM, Chen HS, Wang FF, Yeh CC, Yang CC. Iodine Concentration in the Breast Milk and Urine as Biomarkers of Iodine Nutritional Status of Lactating Women and Breastfed Infants in Taiwan. Nutrients. 2023 Sep 25;15(19):4125. (IF:5.9)
  31. Chang LH, Chu CH, Huang CC, Lin LY*. Soluble tumor necrosis factor receptor type 1 predicts cardiorenal outcomes and better associated with distinct cardiovascular or renal outcomes than precedential renal or cardiovascular events in type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2023 Oct 29;14:20420188231207345. (IF:3.8)
  32. Hang JF, Chen JY, Kuo PC, Lai HF, Lee TL, Tai SK, Kuo CS*, Chen HS, Li WS, Li CF. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases. Mod Pathol. 2023 Sep;36(9):100242. (IF:7.5)
  33. 1,5Yen FS, Yu TS, Hsu CC, Hwu CM*. Reply to the Letter to the Editor: GLP-1 Receptor Agonist Treatment in Liver Cirrhosis. Clinical Gastroenterology and Hepatology2023 Sep 22:S1542-3565(23)00753-X (IF:12.6)
  34. 1Yen FS, Wei JC, Yu TS, Hung YT, Hsu CC, Hwu CM*. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes. JAMA Netw Open. 2023 Dec 1;6(12):e2348431. (IF:13.8)
  35. 1,5Yen FS, Hou MC, Wei JC, Shih YH, Hwu CM*, Hsu CC. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes. BMC Med. 2024;22(1):8. (IF: 9.3)
  36. 1Chiu LT, Lin YL, Wang CH, Hwu CM, Liou HH, Hsu BG. Electrochemical Skin Conductance by Sudoscan in Non-Dialysis Chronic Kidney Disease Patients. Journal of Clinical Medicine. 2024; 13(1):187.(IF:3.9)
  37. 1Wang WT, Wu TH, Er LK, Huang CW, Tu KH, Fan KC, Tsai CH, Wang SY, Wu CY, Huang SH, Liu HW, Tseng FY, Wu WC, Chang CC, Cheng HM, Lin LY, Chueh JS, Lin YH, Hwu CM, Wu VC. Recent progress in unraveling cardiovascular complications associated with Primary aldosteronism: A succinct review. Hypertens Res. 2023 (accepted) (IF: 5.4)
  38. 1Chen YY, Huang SC, Pan CT, Peng KY, Lin LY, Chan CK, Shun CT. The predictors of long-term outcomes after targeted therapy for primary Aldosteronism. J Formos Med Assoc. 2023 Dec 14:S0929-6646(23)00471-0.( IF: 3.2)
  39. 1 Kuo CS …et al. Residual Risk of Cardiovascular Complications in Statin-Using Patients with Type 2 Diabetes: The Taiwan Diabetes Registry Study. Lipids Health Dis (accepted) (IF: 4.5)
  40. 1,5Lim LL, Lau ESH, Kong APS, …, Sheu WHH, …et al. Gender-associated cardiometabolic risk profiles and health behaviors in patients with type 2 diabetes: a cross-sectional analysis of the Joint Asia Diabetes Evaluation (JADE) program. Lancet Reg Health West Pac. 2022 Dec 19;32:100663. (IF: 7.1)
  41. Chen F, Wang X, Jang SK, Quach BC, …, Sheu WH, Sims M, …et al. Multi-ancestry transcriptome-wide association analyses yield insights into tobacco use biology and drug repurposing. Nat Genet. 2023 Feb;55(2):291-300. (IF: 30.8)
  42. 1,5 Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, …et al. EMPRISE Europe and Asia Study Group. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Metab. 2023 Mar;49(2):101418. (IF: 7.2)
  43. 1,5 Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, …, Sheu WH, Speake C, Stanislawski MA, Steenackers N, …et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023 Oct;29(10):2438-2457. (IF: 82.9)


B. Refereed Papers Not Included in Science Citation Index:

  1. 2,4Lee, Po-Sheng; Lin, Chun-Hsing; Chen, Ting-Yu; Lee, Ya-Chun; Hwu, Chii-Min*; Kuo, Chin-Sung. Effectiveness of Insulin Glargine Plus Lixisenatide (iGlarLixi) in Improving Glycemic Control in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Observational Study. Source: Formosan Journal of Endocrinology and Metabolism. 2023(accepted) (IF: 0)
  2. 2,4Chen HS*. Five-year effect of health education before Chinese New Year’s holidays on glycemic control in patients with type 2 diabetes.

Source: Formosan Journal of Endocrinology and Metabolism. Accepted on Jan 30, 2023. (IF: 0)

  1. 1,5 Misra S, Wagner R, Ozkan B, …, Sheu WH, Hansen T, Stefan N, Goodarzi MO, Ray D, … et al. Systematic review of precision subclassification of type 2 diabetes. medRxiv [Preprint]. 2023 Apr 20:2023.04.19.23288577. 2023.04.19.23288577. (IF: 0)